ValuEngine cut shares of Viking Therapeutics (NASDAQ:VKTX) from a hold rating to a sell rating in a report released on Friday morning.

VKTX has been the topic of several other reports. Maxim Group set a $5.00 price objective on shares of Viking Therapeutics and gave the company a buy rating in a report on Thursday, August 10th. Roth Capital set a $6.00 price objective on shares of Viking Therapeutics and gave the company a buy rating in a report on Wednesday, November 29th. Finally, HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Viking Therapeutics in a report on Friday, November 10th.

Viking Therapeutics (NASDAQ:VKTX) opened at $2.85 on Friday. Viking Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $3.24.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.03). equities research analysts expect that Viking Therapeutics will post -0.86 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new position in shares of Viking Therapeutics in the third quarter valued at about $108,000. Virtu KCG Holdings LLC acquired a new position in shares of Viking Therapeutics in the second quarter valued at about $124,000. Renaissance Technologies LLC grew its stake in shares of Viking Therapeutics by 62.9% in the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock valued at $388,000 after acquiring an additional 102,600 shares in the last quarter. Sphera Funds Management LTD. acquired a new position in shares of Viking Therapeutics in the third quarter valued at about $554,000. Finally, Sabby Management LLC acquired a new position in shares of Viking Therapeutics in the second quarter valued at about $525,000. Institutional investors and hedge funds own 7.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/05/viking-therapeutics-vktx-downgraded-to-sell-at-valuengine.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related stocks with our FREE daily email newsletter.